Variables | Laboratory confirmed tuberculosis Referencea | Laboratory confirmed influenza | Laboratory confirmed tuberculosis-influenza co-infection | |||||
---|---|---|---|---|---|---|---|---|
n/N (%) | RRRb | ARRRc(95% CI) | n/N (%) | RRRb | ARRRc(95% CI) | |||
Age group (years) | 0-4 | 47/423 (11) | 46/275 (10) | Reference | Reference | 8/34 (22) | Reference | Reference |
5-24 | 44/423 (10) | 28/275 (11) | 0.6 (0.3-1.2) | 1.3 (0.6-2.9) | 3/34 (9) | 0.4 (0.1-1.6) | 0.5 (0.1-2.5) | |
25-44 | 231/423 (55) | 121/275 (44) | 0.5 (0.3-0.8) | 1.5 (0.8-2.8) | 18/34 (53) | 0.5 (0.2-1.2) | 0.5 (0.2-1.7) | |
45-64 | 86/423 (20) | 57/275 (21) | 0.7 (0.4-1.1) | 1.3 (0.7-2.5) | 4/34 (12) | 0.3 (0.1-0.9) | 0.3 (0.1-2.5) | |
65+ | 15/423 (3) | 23/275 (8) | 1.6 (0.7-3.4) | 3.9 (1.6-9.8) | 1/34 (3) | 0.3 (0.04-3.4) | 9.53e-07 | |
Sex | Female | 247/423 (58) | 176/275 (64) | Reference | 20/34 (59) | Reference | ||
Male | 176/176 (42) | 99/275 (36) | 0.8 (0.6-1.1) | 14/34 (41) | 1.0 (0.5-1.9) | |||
Site | Chris Hani Baragwanath | 124/423 (29) | 169/275 (61) | Reference | 17/34 (50) | Reference | ||
Mapulaneng & Matikwana | 21/423 (5) | 11/275 (4) | 0.4 (0.2-0.8) | 2/34 (6) | 0.7 (0.1-3.2) | |||
Edendale | 48/423 (11) | 22/275 (8) | 0.3 (0.2-0.6) | 1/34 (3) | 0.2 (0.01-1.2) | |||
Klerksdorp/Tshepong | 230/423 (54) | 73/275 (27) | 0.2 (0.2-0.3) | 14/34 (41) | 0.4 (0.2-0.9) | |||
HIV status | Negative | 82/392 (21) | 99/257 (39) | Reference | Reference | 7/32 (22) | Reference | Reference |
Positive | 310/392 (79) | 158/257 (61 | 0.4 (0.3-0.6) | 0.6 (0.4-0.9) | 25/32 (78) | 0.9 (0.4-2.3) | 1.6 (0.5-4.9) | |
Underlying medical conditionsd | No | 394/423 (93) | 240/275 (87) | Reference | 32/34 (94) | Reference | ||
Yes | 29/423 (7) | 35/275 (13) | 1.98 (1.2-3.3) | 2/34 (6) | 0.8 (0.2-3.7) | |||
Duration of symptoms prior to admission | <7 | 166/412 (40) | 194/275 (71) | Reference | Reference | 24/33 (73) | Reference | Reference |
≥7 | 246/412 (60) | 81/275 (29) | 0.3 (0.2-0.4) | 0.4 (0.2-0.4) | 9/33 (27) | 0.3 (0.1-0.6) | 0.3 (0.1-0.7) | |
Pneumoccocal co-infection on PCRe | No | 371/388 (96) | 233/246 (95) | Reference | Reference | 29/30 (97) | ||
Yes | 17/388 (4) | 13/246 (5) | 1.2 (0.6-2.6) | 1/30 (3) | 0.8 (0.1-5.8) | |||
Oxygen therapy | No | 313/423 (74) | 158/275 (57) | Reference | Reference | 24/34 (71) | Reference | Reference |
Yes | 110/423 (26) | 117/275 (43) | 2.1 (1.5-2.9) | 1.9 (1.3-2.8) | 10/34 (29) | 1.2 (0.5-2.6) | 0.97 (0.4-2.3) | |
Tuberculosis treatment | No | 185/422 (44) | 243/274 (89) | Reference | 20/34 (59) | Reference | ||
Yes | 237/422 (56) | 31/274 (11) | 0.1 (0.1-0.2) | 14/34 (41) | 0.5 (0.3-1.1) | |||
Hospital duration (days) | ≤ | 257/420 (61) | 198/274 (72) | Reference | 22/33 (67) | Reference | Reference | |
>7 | 163/420 (39) | 76/274 (28) | 0.6 (0.4-0.8) | 0.6 (0.4-0.9) | 11/33 (33) | 0.8 (0.4-1.7) | 0.7 (0.3-1.5) | |
Died | No | 391/422 (73) | 265/274 | Reference | Reference | 30/34 (88) | Reference | Reference |
Yes | 31/422 (7) | 9/274 | 0.4 (0.2-0.9) | 0.5 (0.2-1.1) | 4/34 (12) | 1.7 (0.6-5.1) | 3.2 (1.1-10.0) |